990 reports: what the FDA numbers on compounded GLP-1s mean
Published October 26, 2026. About US data. Source and date listed below.
Quick take: by the end of May 2026 the FDA had received 990 reports about compounded semaglutide and over 730 about compounded tirzepatide. A report is a signal, not proof.
What the numbers are
These are adverse event reports. The FDA says a report does not prove the drug caused the problem, and that the real count may be higher than what is reported. Some reported dosing errors led to hospitalization, and an expert cited rising poison control calls over four years from people misdosing compounded products.
Why the research label shows up here
The same article notes that unapproved peptides are being marketed for weight loss, muscle growth and recovery, and that some carry "research use only" or "not for human consumption" labels. The FDA has also found fraudulent products that named pharmacies which never made them.
Questions experts suggest asking
- Why is a compounded version being prescribed?
- Which pharmacy makes it?
- Is the peptide approved for human use at all?
The article adds that a brief online or chat consultation does not count as real medical supervision.
Read more: how to read peptide news.
Ready to order?
Paste it in the Promo code box in the order summary at checkout, then press Apply. Confirm the discount line before you pay.
Common questions
Does an adverse event report prove harm?
No. The FDA says a report does not prove the drug caused the problem.
Are the numbers complete?
The FDA says they may undercount real problems.
Is this medical advice?
No. It is a news summary.
Sources
Summarised in my own words. Read the originals for the full detail.